Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals (SWC)

Buy
Sell
Company name:Celadon Pharmaceuticals Plc
EPIC:SWC (delisted)Trading Currency:GBP
Market Sector:ISIN:
Market Segment:Share Type:DE
WWW Address:www.summerwaycapital.co.ukDescription:Ordinary Shares
Industry Sector:EQUITY INVESTMENT INSTRUMENTS
 Price Price Change [%] Bid Offer Open High Low Volume
 147.50 images.advfn.com/imagesnew/2/gb/dot 0.0 [0.00] 140.00 155.00 - - - -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 1,184.93 8.03 -0.03 -3.60 - - - -

Celadon Pharmaceuticals Key Figures

(at previous day's close)
Market Cap.1,184.93m
Shares In Issue8.03m
Prev. Close147.50
PE Ratio- 
Dividend Yield-%
EPS - basic-3.60p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-2.17p
Return On Equity (ROE)-3.40%
Operating Margin-%
PEG Factor- 
EPS Growth Rate-%
Dividends PS Growth Rate-%
Net Debt-5.61m
Gross Gearing0.58%
Quick Assets5.66m
Net Working Capital5.64m
Intangibles / Fixed Assets-%
Turnover PS-p
Pre-Tax Profit PS-2.38p
Retained Profit PS-2.38p
Cash PS70.30p
Net Cash PS70.04p
Net Tangible Asset Value PS *70.09p
Net Asset Value PS70.09p
Spread15.00 (9.68%) 
* Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies.

Celadon Pharmaceuticals Balance Sheet

L^SWC:Liabilities+EQL^SWC:Assets

Share Price Performance

Sorry No Data Available

Share Price Chart (5 years)

Celadon Pharmaceuticals Historic Returns

Sorry No Data Available

Celadon Pharmaceuticals Key Management Ratios

Celadon Pharmaceuticals Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 209.22 
Tobin's Q Ratio (excl. intangibles)209.22 
Dividend Yield-%
Market-to-Book Ratio210.45 
Price-to-Pre-Tax Profit PS-6,193.43 
Price-to-Retained Profit PS-6,193.43 
Price-to-Cash Flow PS-6,808.01 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS210.45 
Price-to-Cash PS209.80 
Net Working Capital PS70.24 
Price Pct to Working Capital PS210.00%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Celadon Pharmaceuticals Financial Ratios

(Leverage Ratios)
Debt Ratio0.21%
Debt-to-Equity Ratio0.00 
Debt-to-Equity Ratio (excl. Intgbl)0.00 
Debt-to-Equity Market Value0.00 
Net Gearing-99.14%
Net Gearing (excl. Intangibles)-99.14%
Gross Gearing0.58%
Gross Gearing (excl. Intangibles)0.58%
Gearing Under 1 Year0.37%
Gearing Under 1 Year (excl. Intgbl)0.37%
Assets/Equity1.01 
Cash/Equity100.31 
(Liquidity Ratios)
Net Working Capital to Total Assets99.63%
Current Ratio270.45 
Quick Ratio (Acid Test)270.45 
Liquidity Ratio269.70 
Cash & Equiv/Current Assets99.72%
(Solvency Ratios)
Enterprise Value1,179.29m
CFO/Sales- 
CFO/Attributable Profit- 
CFO/Assets-0.03 
CFO/Debt-5.28 
Total Debt/Equity Market Value0.00 
Total Debt/Sales- 
Total Debt/Pre-Tax Profit-0.17 
Total Debt0.03m
Total Debt/Net Current Assets0.01%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs- 
Beta (60-Mnth)Beta (36-Mnth)
-0.02940.0485

Celadon Pharmaceuticals Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-3.39%
Return On Assets (ROA)-3.38%
Net Profit Margin-%
Assets Turnover- 
Return On Equity (ROE)-3.40%
Return On Investment (ROI)-3.39%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-%
(Asset Utilisation Multiples)
Shareholders Equity Turnover- 
Fixed Assets Turnover- 
Current Assets Turnover- 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales- 
Debtors-to-Sales-%
Debt Collection Period-Days

Celadon Pharmaceuticals Dividends

Sorry No Data Available

Celadon Pharmaceuticals Fundamentals
 31 Aug 2019 (GBP)
turnover--m
pre tax profit-0.19-m
attributable profit-0.19-m
retained profit-0.19-m
eps - basic (p)-3.60 
eps - diluted (p)-3.60 
dividends per share- 

Celadon Pharmaceuticals Balance Sheet

 31 Aug 2019 (GBP)
L^SWC:Liabilities+EQL^SWC:Assets
 31 Aug 2019 (GBP)
ASSETS
fixed assets fixed assets--%m
intangibles intangibles--%m
fixed investments fixed investments--%m
current assets - other current assets - other--%m
stocks stocks--%m
debtors debtors0.020.28%m
cash & securities cash & securities5.6599.72%m
TOTAL5.66100%m
LIABILITIES
creditors - short creditors - short0.020.37%m
creditors - long creditors - long0.010.21%m
creditors - other creditors - other--%m
subordinated loans subordinated loans--%m
insurance funds insurance funds--%m
TOTAL0.030.58%m
EQUITY
ord cap, reserves ord cap, reserves5.6399.42%m
prefs, minorities prefs, minorities--%m
TOTAL5.6399.42%m
OTHER
NAV Basic- 
NAV Diluted- 

Celadon Pharmaceuticals Cash Flow Statement

31 Aug 2019 (GBP)
Operating CF-0.17m
Pre-Financing CF-0.17m
Retained CF5.65m

Celadon Pharmaceuticals Brokers

NameActivityTypeMnemonicCode
Liberum Capital LimitedMarket Maker(MMF)Broker/DealerLIBCLCAPGB21
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
LSE
SWC
Celadon Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220628 13:22:02